Castle Biosciences (CSTL) Liabilities and Shareholders Equity (2018 - 2026)

Castle Biosciences has disclosed Liabilities and Shareholders Equity across 9 years of filings, most recently posting $547.8 million for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $547.8 million, up 9.19% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.2 billion (up 9.78% YoY), and the FY2025 annual result was $578.6 million, up 8.91% from the prior year.
• Liabilities and Shareholders Equity came in at $547.8 million for Q1 2026 at Castle Biosciences, down from $578.6 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $578.6 million in Q4 2025 to a low of $425.4 million in Q2 2023.
• The 5-year median for Liabilities and Shareholders Equity is $458.5 million (2024), against an average of $486.9 million.
• Across the five-year window, Liabilities and Shareholders Equity retreated 7.19% in 2023 and rose 18.01% in 2024, its largest moves.
• Castle Biosciences' Liabilities and Shareholders Equity stood at $447.3 million in 2022, then gained by 1.34% to $453.3 million in 2023, then climbed by 17.18% to $531.2 million in 2024, then rose by 8.91% to $578.6 million in 2025, then decreased by 5.32% to $547.8 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $547.8 million (Q1 2026), $578.6 million (Q4 2025), and $562.8 million (Q3 2025), per Business Quant data.